Fine Biotech - FineTest - FN Test

FineTest is the brand name of Wuhan Fine Biotech Co., Ltd., a biotechnology company based in Wuhan, China. Established in 2013, FineTest specializes in developing and manufacturing high-quality life science research reagents, including ELISA kits, antibodies, recombinant proteins, and related reagents.

Product Portfolio

ELISA Kits: FineTest offers over 9,000 ELISA kits covering more than 16 species, including humans, mice, rats, and other species. These kits are designed for various applications such as cytokine detection, hormone measurement, tumor marker analysis, and infectious disease diagnostics.
Antibodies: The company provides a wide range of primary and secondary antibodies validated for applications like ELISA, Western blotting (WB), immunohistochemistry (IHC), and flow cytometry.
Recombinant Proteins: FineTest supplies recombinant proteins, including cytokines, immune checkpoint proteins, and proteins for stem cell culture, catering to diverse research needs.
Reagents: The company also offers various reagents to support research in areas such as metabolism, signal transduction, immunology, neuroscience, and more.

Browse Fine Biotech - FineTest - FN Test Products

1,25-DVD3 (1,25-Dihydroxy Vitamin D3) ELISA Kit

SKU: EU2628|Size: 96 Tests

12-HETE (12-Hydroxyeicosatetraenoic Acid) ELISA Kit

SKU: EU3131|Size: 96 Tests

14,15-EET/DHET ELISA Kit

SKU: EU2642|Size: 96 Tests

15-HETE (15-Hydroxyeicosatetraenoic Acid) ELISA Kit

SKU: EU2612|Size: 96 Tests

16,16-Dimethyl-PGE2 (16,16-dimethyl Prostaglandin E2) ELISA Kit

SKU: EU2621|Size: 96 Tests

17-OHP (17-Hydroxyprogesterone) ELISA Kit

SKU: EU0461|Size: 96 Tests

2-ME2 (2-Methoxy Estradiol) ELISA Kit

SKU: EU0251|Size: 96 Tests

24,25-DVD3 (24,25-Dihydroxy Vitamin D3) ELISA Kit

SKU: EU2609|Size: 96 Tests

25-HVD2 (25-Hydroxy Vitamin D2) ELISA Kit

SKU: EU2546|Size: 96 Tests

25-HVD3 (25-Hydroxy Vitamin D3) ELISA Kit

SKU: EU2544-CM|Size: 96 Tests

25-OH VD antibody

SKU: FNab10834|Size: 100 µg

25OH-D (Total 25-OH Vitamin D) ELISA Kit

SKU: EU3593|Size: 96 Tests

27-OHC (27-Hydroxycholesterol) ELISA Kit

SKU: EU2632|Size: 96 Tests

2X PCR Master Mix

SKU: K089|Size: 400 Tests

3-NT (3-Nitrotyrosine) ELISA Kit

SKU: EU2560|Size: 96 Tests

3MH (3-methylhistidine) ELISA Kit

SKU: EU2664|Size: 96 Tests

4% Paraformaldehyde Fix Solution

SKU: IHC-0089-01|Size: 100 mL

4-HNE (4-Hydroxynonenal) ELISA Kit

SKU: EU0187|Size: 96 Tests

5-FAM antibody

SKU: FNab10903|Size: 100 µg

5-HETE (5-Hydroxyeicosatetraenoic Acid) ELISA Kit

SKU: EU0185|Size: 96 Tests

5-HIAA (5-Hydroxyindoleacetic Acid) ELISA Kit

SKU: EU2582|Size: 96 Tests

5-HT antibody

SKU: FNab09928|Size: 100 µg

6*His, His-Tag antibody

SKU: FNab00009|Size: 100 µg

6-hydroxymelatonin sulfate ELISA Kit

SKU: EU3120|Size: 96 Tests

6-keto-PGF1a (6-keto-prostaglandin F1a) ELISA Kit

SKU: EU2572|Size: 96 Tests

7-AAD Reagent (100μg/mL)

SKU: K115-01|Size: 200 Tests

8-OHDG antibody

SKU: FNab11005|Size: 100 µg

8-OHdG (8-Hydroxydeoxyguanosine) ELISA Kit

SKU: EU2548|Size: 96 Tests

8-OHdG (8-Hydroxydeoxyguanosine) high sensitivity ELISA Kit

SKU: EU2548-HS|Size: 96 Tests

8-iso-PGF2α (8-isoprostane) ELISA Kit

SKU: EU2561|Size: 96 Tests

A1BG antibody

SKU: FNab00012|Size: 100 µg

A29L antibody

SKU: FNab10955|Size: 100 µg

A2M antibody

SKU: FNab00340|Size: 100 µg

A35R antibody

SKU: FNab10971|Size: 100 µg

A4GALT antibody

SKU: FNab00014|Size: 100 µg

A4GNT antibody

SKU: FNab00015|Size: 100 µg

AA (Arachidonic Acid) ELISA Kit

SKU: EU2569|Size: 96 Tests

AAAS antibody

SKU: FNab00275|Size: 100 µg

AACS antibody

SKU: FNab00016|Size: 100 µg

AADAT antibody

SKU: FNab00018|Size: 100 µg

AAMDC antibody

SKU: FNab01007|Size: 100 µg

AAMP antibody

SKU: FNab00019|Size: 100 µg

AANAT antibody

SKU: FNab00020|Size: 100 µg

AARS1 antibody

SKU: FNab00276|Size: 100 µg

AARS2 antibody

SKU: FNab00022|Size: 100 µg

AARSD1 antibody

SKU: FNab00023|Size: 100 µg

AASDHPPT antibody

SKU: FNab00024|Size: 100 µg

AATF antibody

SKU: FNab00025|Size: 100 µg

ABAT antibody

SKU: FNab00026|Size: 100 µg

ABCA2 antibody

SKU: FNab00027|Size: 100 µg

ABCA4 antibody

SKU: FNab09922|Size: 100 µg

ABCA7 antibody

SKU: FNab00028|Size: 100 µg

ABCA8 antibody

SKU: FNab00029|Size: 100 µg

ABCB1 antibody

SKU: FNab09805|Size: 100 µg

ABCB10 antibody

SKU: FNab00030|Size: 100 µg

ABCB11 antibody

SKU: FNab10278|Size: 100 µg

ABCB5 antibody

SKU: FNab10874|Size: 100 µg

ABCB6 antibody

SKU: FNab00032|Size: 100 µg

ABCB7 antibody

SKU: FNab00033|Size: 100 µg

ABCB9 antibody

SKU: FNab00034|Size: 100 µg

ABCC1 antibody

SKU: FNab09806|Size: 100 µg

ABCC2 antibody

SKU: FNab05310|Size: 100 µg

ABCC5 antibody

SKU: FNab05311|Size: 100 µg

ABCC6 antibody

SKU: FNab10348|Size: 100 µg

ABCD1 antibody

SKU: FNab00037|Size: 100 µg

ABCD2 antibody

SKU: FNab00038|Size: 100 µg

ABCE1 antibody

SKU: FNab10351|Size: 100 µg

ABCF1 antibody

SKU: FNab00040|Size: 100 µg

ABCF2 antibody

SKU: FNab00041|Size: 100 µg

ABCG1 antibody

SKU: FNab00042|Size: 100 µg

ABCG2 antibody

SKU: FNab00855|Size: 100 µg

ABCG4 antibody

SKU: FNab00043|Size: 100 µg

ABHD1 antibody

SKU: FNab00044|Size: 100 µg

ABHD12B antibody

SKU: FNab00045|Size: 100 µg

ABHD14A antibody

SKU: FNab00046|Size: 100 µg

ABHD14B antibody

SKU: FNab00047|Size: 100 µg

ABHD15 antibody

SKU: FNab00048|Size: 100 µg

ABHD18 antibody

SKU: FNab01116|Size: 100 µg

ABHD2 antibody

SKU: FNab00049|Size: 100 µg

ABHD5 antibody

SKU: FNab00050|Size: 100 µg

ABHD6 antibody

SKU: FNab00051|Size: 100 µg

ABI2 antibody

SKU: FNab00052|Size: 100 µg

ABL2 antibody

SKU: FNab00053|Size: 100 µg

ABLIM1 antibody

SKU: FNab00054|Size: 100 µg

ABLIM2 antibody

SKU: FNab00055|Size: 100 µg

ABRA antibody

SKU: FNab08294|Size: 100 µg

ABRAXAS1 antibody

SKU: FNab02974|Size: 100 µg

ABT1 antibody

SKU: FNab00056|Size: 100 µg

ACAA1 antibody

SKU: FNab00058|Size: 100 µg

ACAA2 antibody

SKU: FNab00059|Size: 100 µg

ACACA antibody

SKU: FNab00077|Size: 100 µg

ACAD10 antibody

SKU: FNab00060|Size: 100 µg

ACAD8 antibody

SKU: FNab00061|Size: 100 µg

ACAD9 antibody

SKU: FNab00062|Size: 100 µg

ACADL antibody

SKU: FNab00063|Size: 100 µg

ACADL-Specific antibody

SKU: FNab00064|Size: 100 µg

ACADM antibody

SKU: FNab00065|Size: 100 µg

ACADS antibody

SKU: FNab00066|Size: 100 µg

ACADSB antibody

SKU: FNab00067|Size: 100 µg

ACADVL antibody

SKU: FNab00068|Size: 100 µg

Recent Breakthroughs

Repurposing caspofungin as a small-molecule inhibitor of Clostridium perfringens α-toxin for treatment of gas gangrene.

Takehara M, Homma Y, Ishihara T, Sakaguchi Y, Kasai Y, Matsumoto K, Nakashima K, Yamaji T, Tanaka Y, Imagawa H, Nagahama M.

Commun Med (Lond)

PMID:41991712

Free PMC article

Background Among pharmaceuticals currently in clinical use, few drugs directly target bacterial toxins. Clostridium perfringens α-toxin, a phospholipase C (PLC), is a major virulence factor responsible for gas gangrene caused by C. perfringens type A. There is a clinical need for small-molecule compounds that inhibit such bacterial toxins. Methods A library of 764 FDA-approved drugs was screened to identify compounds that inhibit the PLC activity of C. perfringens α-toxin. Identified hits were further evaluated for their ability to inhibit α-toxin-induced cytotoxicity in human umbilical vein endothelial cells (HUVECs). Additional in vitro assays were conducted to assess changes in neutrophil activation and cytokine production. In vivo efficacy was evaluated in female C57BL/6J mice (n = 21 or 18 per group) challenged with purified α-toxin or infected with C. perfringens type A. Results The initial screen identifies 21 compounds that inhibit the PLC activity. Among them, micafungin, an antifungal agent, is the only compound that suppresses α-toxin-induced cell death in HUVECs. Micafungin also reduces α-toxin-induced CD11b expression in neutrophils and cytokine release in HUVECs. Caspofungin, another antifungal with similar properties, also inhibits α-toxin-induced cell death and cytokine production. In mouse models, caspofungin, but not micafungin, significantly reduces lethality caused by α-toxin. Caspofungin also improves survival and mitigates muscle damage in mice infected with C. perfringens type A. Conclusions Caspofungin demonstrates promising therapeutic potential as a life-saving treatment for gas gangrene caused by C. perfringens type A, likely through its inhibitory action on α-toxin activity. These findings support the development of new classes of small-molecule therapeutics that directly target bacterial toxins.

Evolving LC-MS hyphenations: strengths, limitations, and emerging trends in bioanalytical applications.

Kapse BP, Soni RP.

Talanta

PMID:42008907

Free PMC article

Hyphenated analytical techniques, particularly liquid chromatography-mass spectrometry (LC-MS), play a central role in addressing the increasing complexity of modern bioanalytical challenges. Recent advancements in LC-MS hyphenation strategies have significantly improved sample preparation efficiency, analyte enrichment, and overall analytical performance. The integration of ion mobility spectrometry provides an additional orthogonal separation dimension, particularly effective for drug metabolism research and isomer discrimination. Furthermore, capillary electrophoresis hyphenation enables effective analysis of polar and charged metabolites, while ambient ionization approaches such as DESI and DART support rapid screening with minimal sample preparation. Tandem setups involving UV, fluorescence, and NMR provide essential layers of structural confirmation. Additionally, the shift toward microfluidic lab-on-a-chip platforms enables miniaturization, thereby reducing sample volume requirements and increasing analytical throughput. Despite these advances, challenges related to instrumental complexity, data interpretation, and regulatory harmonization continue to limit broader translation into routine practice. Collectively, these developments highlight the transformative potential of LC-MS while also emphasizing critical gaps that will shape future bioanalytical advancements.

Artificial Intelligence for Predicting Small-Molecule Bioactive Conformations.

Liu Y, Chen S, Lin K, Gao S, Li X.

J Chem Inf Model

PMID:41991475

Free PMC article

Precise prediction of bioactive conformations represents a central challenge in drug discovery. Traditional computational methods often rely on the assumption that the global minimum energy state corresponds to the bioactive conformation─a hypothesis with inherent limitations. Data-driven artificial intelligence (AI) models have revolutionized research methodologies in this domain. By learning the implicit probability distributions of conformations, AI demonstrates the potential to achieve high-precision predictions of bioactive structures. This review systematically surveys technical advancements ranging from geometric regression to generative and conditional generative models, analyzing their effectiveness in benchmarks and de novo design experiments. We deeply explore critical challenges, including data sparsity, sampling efficiency, generation capability, and interpretability. Finally, we provide an outlook on bridging the gap from "structural prediction" to "functional design" through the construction of dynamic data sets, the development of efficient algorithms, and the implementation of human-in-the-loop collaborative decision-making systems.

Lack of tetrodotoxin analogues and individual metabolomic profiling of the cryptic frog Colostethus imbricolus.

Gonzalez M, Palacios-Rodriguez P, Carazzone C.

PLoS One

PMID:41990106

Free PMC article

Poison frogs (Dendrobatoidea) are characterized by the great diversity of alkaloids discovered in their skin. However, most of these alkaloids have been found in brightly colored species and there is a wide lack of knowledge of alkaloid profiles in the less colorful species. Previous finding of paralytic tetrodotoxins (TTXs) in only two cryptically colored species from the genus Colostethus, establishes the unique occurrence of hydrophilic alkaloids in the superfamily Dendrobatoidea. Unpublished results using extracts from Colostethus imbricolus, demonstrated that this species contains paralysis-producing substances, after intraperitoneal injection of mice. To analyze their skin metabolites and to determine if they correspond to TTX, or TTX analogues, we have employed a TTX-targeted separation in normal phase gradient, and an untargeted profiling in reversed-phase gradient. After performing both analyses, neither TTX nor TTX-analogues were detected in C. imbricolus. In contrast, other metabolites were separated, allowing the extraction of 76 adducts common to both analyses, being 33 of them tentatively annotated as amphibian alkaloids, eight as amphibian metabolites different from alkaloids and 25 that matched with natural products from the DNP. A total of 10 common molecular formulas remained non-annotated. The absence of MS/MS spectra for these adducts requires their structures to be confirmed in future analyses, following the completion of targeted MS/MS acquisition. After analyzing the inter-individual variation of six specimens, it was demonstrated that the skin metabolome differs between males and females of C. imbricolus. Our results lead us to conclude that TTX is not the only paralyzing compound in dendrobatid frogs and that more work should be undergone to identify this phenomenon. A notable additional outcome of this study is the first successful separation of TTX on an SB-CN column using a normal-phase gradient, suggesting a potential useful approach for TTX-targeted separation.

Targeting S1P signaling for drug development.

Liu Y, Song Y, Wang Y, Wang J, Yang K.

Drug Discov Today

PMID:42000126

Free PMC article

Sphingosine-1-phosphate (S1P), a downstream metabolite of the sphingolipid pathway, exerts diverse biological functions, is implicated in a wide spectrum of diseases, and has been shown to have central roles in regulating cell proliferation, migration, and immune cell trafficking. Five agonists of its receptor have been approved for the treatment of multiple sclerosis, and an inhibitor targeting its production is currently undergoing clinical trials for cancer therapy. Here, we discuss the modulators and their preliminary structure-activity relationships in terms of the generation, transportation, and degradation of S1P.